Literature DB >> 21726937

Preoperative analysis of 11q loss using circulating tumor-released DNA in serum: a novel diagnostic tool for therapy stratification of neuroblastoma.

Shigeki Yagyu1, Tomoko Iehara, Takahiro Gotoh, Mitsuru Miyachi, Yoshiki Katsumi, Ken Kikuchi, Kunihiko Tsuchiya, Shinya Osone, Hiroshi Kuroda, Tohru Sugimoto, Tadashi Sawada, Hajime Hosoi.   

Abstract

Allelic deletion of the long arm of chromosome 11 (11q loss) is closely associated with the prognosis of neuroblastoma (NB). Here we examined 11q loss using tumor-released DNA fragments in the sera of 24 cases. The allelic intensity score of a panel of polymorphic markers in 11q23 in serum DNA was significantly different between the 11q loss-positive group and the11q loss-negative group. The 11q loss-positive and -negative groups did not overlap when a cut-off value of 0.5 was chosen for the allelic intensity score. Our serum-based 11q loss analysis could predict the allelic status of 11q in tumors.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21726937     DOI: 10.1016/j.canlet.2011.05.032

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

Review 1.  Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies.

Authors:  Samuel D Abbou; David S Shulman; Steven G DuBois; Brian D Crompton
Journal:  Pediatr Blood Cancer       Date:  2019-01-06       Impact factor: 3.167

2.  Circulating Cell-Free DNA Assessment in Biofluids from Children with Neuroblastoma Demonstrates Feasibility and Potential for Minimally Invasive Molecular Diagnostics.

Authors:  Marco Lodrini; Jasmin Wünschel; Theresa M Thole-Kliesch; Maddalena Grimaldi; Annika Sprüssel; Rasmus B Linke; Jan F Hollander; Daniela Tiburtius; Annette Künkele; Johannes H Schulte; Erwin Lankes; Thomas Elgeti; Patrick Hundsdörfer; Kathy Astrahantseff; Thorsten Simon; Angelika Eggert; Hedwig E Deubzer
Journal:  Cancers (Basel)       Date:  2022-04-21       Impact factor: 6.575

Review 3.  Circulating Tumor DNA in Pediatric Cancer.

Authors:  Louise Doculara; Toby N Trahair; Narges Bayat; Richard B Lock
Journal:  Front Mol Biosci       Date:  2022-05-12

Review 4.  Biomarkers in Neuroblastoma: An Insight into Their Potential Diagnostic and Prognostic Utilities.

Authors:  Fatima Shawraba; Hussein Hammoud; Yara Mrad; Zahraa Saker; Youssef Fares; Hayat Harati; Hisham F Bahmad; Sanaa Nabha
Journal:  Curr Treat Options Oncol       Date:  2021-09-27

Review 5.  Opportunities and challenges of circulating biomarkers in neuroblastoma.

Authors:  Ricky M Trigg; Jacqui A Shaw; Suzanne D Turner
Journal:  Open Biol       Date:  2019-05-31       Impact factor: 6.411

6.  Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages.

Authors:  Antonio Juan Ribelles; Sandra Barberá; Yania Yáñez; Pablo Gargallo; Vanessa Segura; Bárbara Juan; Rosa Noguera; Marta Piqueras; Victoria Fornés-Ferrer; Jaime Font de Mora; Adela Cañete; Victoria Castel
Journal:  Sci Rep       Date:  2019-09-24       Impact factor: 4.379

7.  Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.

Authors:  Zhi-Xia Yue; Tian-Yu Xing; Chao Gao; Shu-Guang Liu; Wen Zhao; Qian Zhao; Xi-Si Wang; Mei Jin; Xiao-Li Ma
Journal:  Cancer Commun (Lond)       Date:  2019-11-04

8.  The REST gene signature predicts drug sensitivity in neuroblastoma cell lines and is significantly associated with neuroblastoma tumor stage.

Authors:  Jianfeng Liang; Pan Tong; Wanni Zhao; Yaqiao Li; Li Zhang; Ying Xia; Yanbing Yu
Journal:  Int J Mol Sci       Date:  2014-06-25       Impact factor: 5.923

9.  Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.

Authors:  Shigeki Yagyu; Tomoko Iehara; Shiro Tanaka; Takahiro Gotoh; Akiko Misawa-Furihata; Tohru Sugimoto; Wendy B London; Michael D Hogarty; Satoshi Teramukai; Akira Nakagawara; Eiso Hiyama; John M Maris; Hajime Hosoi
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.